<p>Rallybio（纳斯达克：RLYB - 获取免费报告）预计将在 2026 年 5 月 12 日星期二市场开盘前公布其 2026 年第一季度业绩。分析师预计该公司将宣布每股收益为（$1.20），季度收入为$0.2270 百万。投资者被鼓励查看该公司即将发布的 2026 年第一季度财报概览页面，以获取关于定于 2026 年 5 月 7 日东部时间上午 7:00 的电话会议的最新信息。</p>
<p>Rallybio（纳斯达克：RLYB - 获取免费报告）上一次发布季度财报是在 3 月 16 日星期一。该公司报告的季度每股收益为（$1.03），超出分析师共识预期的（$1.04）$0.01。该季度的收入为$0.22 百万，而共识预期为$0.10 百万。Rallybio 的净利润率为负的 1,046.39%，股本回报率为负的 56.93%。</p>
<h2>Rallybio 股价下跌 0.5%</h2>
<p>Rallybio 股票在星期二的午盘交易中下跌$0.07，达到$14.05。该公司的股票交易量为 276,372 股，而其平均交易量为 241,753 股。该公司的市值为 7435 万美元，市盈率为-5.47，贝塔值为-1.10。该公司的 50 日移动平均价格为$8.64，200 日移动平均价格为$6.44。Rallybio 的 12 个月低点为$2.16，12 个月高点为$15.31。</p>
<h2>华尔街分析师预测增长</h2>
<p>另外，华尔街 Zen 在 3 月 28 日星期六的报告中将 Rallybio 的股票评级上调至 “持有”。一位研究分析师对该股票给予了卖出评级，根据 MarketBeat.com 的数据，该股票目前的共识评级为 “卖出”。</p>
<p><strong>查看我们对 Rallybio 的最新股票分析</strong></p>
<h2>对 Rallybio 的对冲基金看法</h2>
<p>一些对冲基金最近增加或减少了对该公司的持股。Renaissance Technologies LLC 在第四季度将其在 Rallybio 的持股增加了 16.9%。Renaissance Technologies LLC 现在拥有 835,692 股该公司的股票，价值 573,000 美元，在上个季度购买了额外的 120,892 股。Citadel Advisors LLC 在第三季度将其在 Rallybio 的持股增加了 576.1%。Citadel Advisors LLC 现在拥有 438,705 股该公司的股票，价值 219,000 美元，在上个季度购买了额外的 373,821 股。Geode Capital Management LLC 在第四季度将其在 Rallybio 的持股增加了 1.2%。Geode Capital Management LLC 现在拥有 248,005 股该公司的股票，价值 170,000 美元，在上个季度购买了额外的 2,996 股。Susquehanna International Group LLP 在第三季度将其在 Rallybio 的持股增加了 485.9%。Susquehanna International Group LLP 现在拥有 136,294 股该公司的股票，价值 68,000 美元，在上个季度购买了额外的 113,031 股。最后，XTX Topco Ltd 在第四季度将其在 Rallybio 的持股增加了 64.6%。XTX Topco Ltd 现在拥有 97,313 股该公司的股票，价值 67,000 美元，在上个季度购买了额外的 38,205 股。机构投资者和对冲基金持有该公司 90.34% 的股份。</p>
<h2>Rallybio 公司简介</h2>
<p>（获取免费报告）</p>
<p>Rallybio Therapeutics, Inc（纳斯达克：RLYB）是一家临床阶段的生物技术公司，专注于开发和商业化针对罕见遗传疾病患者的治疗方案。该公司的科学方法利用多种模式，包括单克隆抗体、小分子和酶替代，以解决免疫缺陷、代谢紊乱和皮肤病等领域的高未满足需求的疾病。Rallybio 的产品管线旨在通过注册临床试验推进，目标是为目前缺乏或没有批准治疗方案的患者提供首创或最佳治疗。</p>
<p>Rallybio 的主要项目之一是 RBX-100，一种针对先天性无胸腺症的研究性疗法，这是一种罕见的儿童免疫缺陷病。</p>
<h2>了解更多</h2>
<ul>
<li>我们更看好的五只股票比 Rallybio 更好</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/EarningsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9UkxZQg?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" width="650" height="325" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/EarningsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9UkxZQg"/></p>
<p><em>此即时新闻提醒由叙述科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将任何问题或评论发送至 contact@marketbeat.com。</em></p>
<h2>你现在应该投资$1,000 在 Rallybio 吗？</h2>
<p>在你考虑 Rallybio 之前，你需要听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只股票，顶级分析师正在悄悄地向客户推荐在更广泛的市场注意到之前立即购买……而 Rallybio 并不在名单上。</p>
<p>虽然 Rallybio 目前在分析师中被评为卖出，但顶级分析师认为这五只股票更值得购买。</p>
<p>查看这五只股票</p>

RLYB

标普生物技术 ETF - SPDR

纽交所高增长板生物技术指数 ETF - First Trust

医疗业 ETF - Vanguard

2 倍做多纳斯达克生物技术 ETF - ProShares

标普生物技术 3 倍做多 - Direxion

纳斯达克生物科技指数 ETF - iShares Nasdaq

IBBQ

动态生物技术与基因组 ETF - Invesco

生物科技 ETF - VanEck Vectors

<p>Rallybio（纳斯达克代码：RLYB）将于 5 月 12 日公布 2026 年第一季度财报，分析师预测每股亏损 1.20 美元，收入为 22.7 万美元。该公司最近报告了 2025 年第一季度每股亏损 1.03 美元，超出预期。Rallybio 的股票略有下滑，目前交易价格为 14.05 美元，市值为 7435 万美元。机构投资者持有 90.34% 的股份。尽管最近被升级为 “持有” 评级，但分析师的共识仍然是 “卖出”。Rallybio 专注于罕见遗传疾病的治疗</p>

<p>Rallybio (NASDAQ:RLYB - Get Free Report) is expected to be announcing its Q1 2026 results before the market opens on Tuesday, May 12th. Analysts expect the company to announce earnings of ($1.20) per share and revenue of $0.2270 million for the quarter. Investors are encouraged to explore the company's upcoming Q1 2026 earning overview page for the latest details on the call scheduled for Thursday, May 7, 2026 at 7:00 AM ET.</p>
<div class="lb-trans"><p>Rallybio（纳斯达克：RLYB - 获取免费报告）预计将在 2026 年 5 月 12 日星期二市场开盘前公布其 2026 年第一季度业绩。分析师预计该公司将宣布每股收益为（$1.20），季度收入为$0.2270 百万。投资者被鼓励查看该公司即将发布的 2026 年第一季度财报概览页面，以获取关于定于 2026 年 5 月 7 日东部时间上午 7:00 的电话会议的最新信息。</p>
</div><p>Rallybio (NASDAQ:RLYB - Get Free Report) last released its quarterly earnings results on Monday, March 16th. The company reported ($1.03) earnings per share for the quarter, topping analysts' consensus estimates of ($1.04) by $0.01. The business had revenue of $0.22 million during the quarter, compared to the consensus estimate of $0.10 million. Rallybio had a negative net margin of 1,046.39% and a negative return on equity of 56.93%.</p>
<div class="lb-trans"><p>Rallybio（纳斯达克：RLYB - 获取免费报告）上一次发布季度财报是在 3 月 16 日星期一。该公司报告的季度每股收益为（$1.03），超出分析师共识预期的（$1.04）$0.01。该季度的收入为$0.22 百万，而共识预期为$0.10 百万。Rallybio 的净利润率为负的 1,046.39%，股本回报率为负的 56.93%。</p>
</div><h2>Rallybio Trading Down 0.5%</h2>
<div class="lb-trans"><h2>Rallybio 股价下跌 0.5%</h2>
</div><p>Rallybio stock traded down $0.07 during mid-day trading on Tuesday, reaching $14.05. The company's stock had a trading volume of 276,372 shares, compared to its average volume of 241,753. The firm has a market cap of $74.35 million, a price-to-earnings ratio of -5.47 and a beta of -1.10. The business has a 50 day moving average price of $8.64 and a 200-day moving average price of $6.44. Rallybio has a twelve month low of $2.16 and a twelve month high of $15.31.</p>
<div class="lb-trans"><p>Rallybio 股票在星期二的午盘交易中下跌$0.07，达到$14.05。该公司的股票交易量为 276,372 股，而其平均交易量为 241,753 股。该公司的市值为 7435 万美元，市盈率为-5.47，贝塔值为-1.10。该公司的 50 日移动平均价格为$8.64，200 日移动平均价格为$6.44。Rallybio 的 12 个月低点为$2.16，12 个月高点为$15.31。</p>
</div><h2>Wall Street Analysts Forecast Growth</h2>
<div class="lb-trans"><h2>华尔街分析师预测增长</h2>
</div><p>Separately, Wall Street Zen raised shares of Rallybio to a &#34;hold&#34; rating in a report on Saturday, March 28th. One research analyst has rated the stock with a Sell rating, Based on data from MarketBeat.com, the stock currently has a consensus rating of &#34;Sell&#34;.</p>
<div class="lb-trans"><p>另外，华尔街 Zen 在 3 月 28 日星期六的报告中将 Rallybio 的股票评级上调至 “持有”。一位研究分析师对该股票给予了卖出评级，根据 MarketBeat.com 的数据，该股票目前的共识评级为 “卖出”。</p>
</div><p><strong>Check Out Our Latest Stock Analysis on Rallybio</strong></p>
<div class="lb-trans"><p><strong>查看我们对 Rallybio 的最新股票分析</strong></p>
</div><h2>Hedge Funds Weigh In On Rallybio</h2>
<div class="lb-trans"><h2>对 Rallybio 的对冲基金看法</h2>
</div><p>A number of hedge funds have recently added to or reduced their stakes in the business. Renaissance Technologies LLC lifted its stake in Rallybio by 16.9% in the fourth quarter. Renaissance Technologies LLC now owns 835,692 shares of the company's stock valued at $573,000 after buying an additional 120,892 shares during the last quarter. Citadel Advisors LLC lifted its stake in Rallybio by 576.1% in the third quarter. Citadel Advisors LLC now owns 438,705 shares of the company's stock valued at $219,000 after buying an additional 373,821 shares during the last quarter. Geode Capital Management LLC lifted its stake in Rallybio by 1.2% in the fourth quarter. Geode Capital Management LLC now owns 248,005 shares of the company's stock valued at $170,000 after buying an additional 2,996 shares during the last quarter. Susquehanna International Group LLP lifted its stake in Rallybio by 485.9% in the third quarter. Susquehanna International Group LLP now owns 136,294 shares of the company's stock valued at $68,000 after buying an additional 113,031 shares during the last quarter. Finally, XTX Topco Ltd lifted its stake in Rallybio by 64.6% in the fourth quarter. XTX Topco Ltd now owns 97,313 shares of the company's stock valued at $67,000 after buying an additional 38,205 shares during the last quarter. Institutional investors and hedge funds own 90.34% of the company's stock.</p>
<div class="lb-trans"><p>一些对冲基金最近增加或减少了对该公司的持股。Renaissance Technologies LLC 在第四季度将其在 Rallybio 的持股增加了 16.9%。Renaissance Technologies LLC 现在拥有 835,692 股该公司的股票，价值 573,000 美元，在上个季度购买了额外的 120,892 股。Citadel Advisors LLC 在第三季度将其在 Rallybio 的持股增加了 576.1%。Citadel Advisors LLC 现在拥有 438,705 股该公司的股票，价值 219,000 美元，在上个季度购买了额外的 373,821 股。Geode Capital Management LLC 在第四季度将其在 Rallybio 的持股增加了 1.2%。Geode Capital Management LLC 现在拥有 248,005 股该公司的股票，价值 170,000 美元，在上个季度购买了额外的 2,996 股。Susquehanna International Group LLP 在第三季度将其在 Rallybio 的持股增加了 485.9%。Susquehanna International Group LLP 现在拥有 136,294 股该公司的股票，价值 68,000 美元，在上个季度购买了额外的 113,031 股。最后，XTX Topco Ltd 在第四季度将其在 Rallybio 的持股增加了 64.6%。XTX Topco Ltd 现在拥有 97,313 股该公司的股票，价值 67,000 美元，在上个季度购买了额外的 38,205 股。机构投资者和对冲基金持有该公司 90.34% 的股份。</p>
</div><h2>Rallybio Company Profile</h2>
<div class="lb-trans"><h2>Rallybio 公司简介</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>（获取免费报告）</p>
</div><p>Rallybio Therapeutics, Inc NASDAQ: RLYB is a clinical‐stage biotechnology company focused on developing and commercializing therapies for people living with rare genetic diseases. The company's scientific approach leverages diverse modalities—including monoclonal antibodies, small molecules and enzyme replacement—to address high‐unmet‐need conditions in areas such as immunodeficiency, metabolic disorders and dermatologic diseases. Rallybio's pipeline is designed to advance through registrational clinical trials with the goal of delivering first‐in‐class or best‐in‐class therapies to patients who currently have limited or no approved treatment options.</p>
<div class="lb-trans"><p>Rallybio Therapeutics, Inc（纳斯达克：RLYB）是一家临床阶段的生物技术公司，专注于开发和商业化针对罕见遗传疾病患者的治疗方案。该公司的科学方法利用多种模式，包括单克隆抗体、小分子和酶替代，以解决免疫缺陷、代谢紊乱和皮肤病等领域的高未满足需求的疾病。Rallybio 的产品管线旨在通过注册临床试验推进，目标是为目前缺乏或没有批准治疗方案的患者提供首创或最佳治疗。</p>
</div><p>Among Rallybio's lead programs is RBX‐100, an investigational therapy for congenital athymia, a rare pediatric immunodeficiency.</p>
<div class="lb-trans"><p>Rallybio 的主要项目之一是 RBX-100，一种针对先天性无胸腺症的研究性疗法，这是一种罕见的儿童免疫缺陷病。</p>
</div><h2>Read More</h2>
<div class="lb-trans"><h2>了解更多</h2>
</div><ul>
<li>Five stocks we like better than Rallybio</li>
</ul>
<div class="lb-trans"><ul>
<li>我们更看好的五只股票比 Rallybio 更好</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/EarningsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9UkxZQg" alt="" original-src="https://www.marketbeat.com/scripts/EarningsChart.ashx?Prefix=NASDAQ&amp;Symbol=RLYB"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻提醒由叙述科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将任何问题或评论发送至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in Rallybio Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资$1,000 在 Rallybio 吗？</h2>
</div><p>Before you consider Rallybio, you'll want to hear this.</p>
<div class="lb-trans"><p>在你考虑 Rallybio 之前，你需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Rallybio wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只股票，顶级分析师正在悄悄地向客户推荐在更广泛的市场注意到之前立即购买……而 Rallybio 并不在名单上。</p>
</div><p>While Rallybio currently has a Sell rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然 Rallybio 目前在分析师中被评为卖出，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>查看这五只股票</p>
</div>

Rallybio (RLYB) 预计将在周二发布季度财报